Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James Moreá>
Companies Commented On
- AtriCure Inc.
- Endologix Inc.
- HeartWare Inc.
- Novadaq Technologies Inc.
- Sunshine Heart Inc.
- Thoratec Corp.
- Vascular Solutions Inc.
Jason Mills is managing director at Canaccord Genuity. He joined Canaccord from First Albany Capital, where he was managing director and senior analyst covering the medical devices sector with a specific focus on the areas of cardiovascular disease, ophthalmology and sleep disorders. Mills previously served as a vice president and senior research analyst with Thomas Weisel Partners, where he covered companies in the ophthalmology and sports medicine/arthroscopy sectors. He holds a Master of Sports Administration from Ohio University and a Bachelor of Arts in economics from Yale University.
Follow the M&A Money to Small- and Mid-Cap Cardiovascular Medtechs: Jason Mills (1/2/14) Some investors' eyes glaze over at the mention of medical devices. But it's time to wake up and focus on the stunning growth opportunities in small- and mid-cap cardiovascular medtech. Canaccord Genuity Managing Director Jason Mills covers companies on the front lines of innovation and in sectors where the trifecta of revenue, margins and reimbursement is achieving biotechlike levels. In this interview with The Life Sciences Report, Mills opens the new year with a discussion of the cardiovascular medtech industry and mentions companies that are probable acquisition candidates.
Deep Value Found in Small Medtech: Jason Mills (4/19/12) Medical device companies need to demonstrate four qualities to be good investment ideas, according to Senior Medical Devices Analyst and Managing Director Jason Mills of Canaccord Genuity. In this exclusive interview with The Life Sciences Report, Mills shares his precise criteria and pinpoints specific growth names that are trading at value levels.
"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino Moreá>